Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldt-jakob disease or diabetes mellitus

Nat Milton (Inventor)

Research output: Patent

Abstract

The present invention is directed to Kissorphin peptides (Tyr-Asn-Trp-Asn-Ser-Phe) and derivatives or analogs thereof that target Amyloid fibril-forming peptides. The Kissorphin peptides are highly specific therapeutic reagents that are useful in detecting, preventing and treating diseases associated with Amyloid fibril-forming peptides, such as Alzheimer's disease, Creutzfeldt-Jakob disease or Diabetes mellitus. According to the invention, a peptide comprises the amino acid sequence defined herein as SEQ ID No. 2, for use in the treatment of a condition associated with Amyloid fibril-forming peptides, wherein the peptide does not directly activate or inhibit the GPR-54 G-protein coupled receptor. Antibodies against Kissorphin peptides and methods for determining whether a subject has, or is predisposed to having, a disorder associated with Amyloid fibril formation are also described.
Original languageEnglish
Patent numberGB2493313
Filing date19/05/11
Publication statusPublished - 2 Jan 2013

Fingerprint

Dive into the research topics of 'Kissorphin peptides for use in the treatment of alzheimer's disease, creutzfeldt-jakob disease or diabetes mellitus'. Together they form a unique fingerprint.

Cite this